Society guideline links: Rh disease in pregnancy

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

International

●World Health Organization (WHO): Abortion care guideline (2022)

●International Federation of Gynecology and Obstetrics (FIGO)/International Confederation of Midwives (ICM): Guidelines for preventing Rhesus disease – A call to action (2021)

Canada

●Choosing Wisely Canada: Do not perform serological weak D testing on antenatal samples with weak or variable RhD typing results (2022)

●Choosing Wisely Canada: Do not repeat prenatal titrations for mothers with clinically significant antibodies (eg, RhD, K) if prediction of fetal cognate antigen typing is feasible and is deemed to be negative (2022)

●National Abortion Federation (NAF): Clinical policy guidelines for abortion care (2022)

●Canadian Blood Services (CBS): Clinical guide to transfusion − Chapter 12: Hemolytic disease of the fetus and newborn and perinatal immune thrombocytopenia (2018)

●Society of Obstetricians and Gynaecologists of Canada (SOGC): Prevention of Rh alloimmunization (2018)

●SOGC: Clinical practice guideline on routine non-invasive prenatal prediction of fetal RHD genotype in Canada – The time is here (2017)

United States

●National Abortion Federation (NAF): Clinical policy guidelines for abortion care (2022)

●Society of Family Planning (SFP): Consensus on Rh testing in early pregnancy (2022)

●American College of Obstetricians and Gynecologists (ACOG) and SFP: Practice bulletin on medication abortion up to 70 days of gestation (2020)

●ACOG: Practice bulletin for the management of alloimmunization during pregnancy (2018)

●ACOG: Practice bulletin for the prevention of Rh D alloimmunization (2017)

●Society for Maternal-Fetal Medicine (SMFM): Clinical guideline #8 on the fetus at risk for anemia – Diagnosis and management (2015)

United Kingdom

●Royal College of Obstetricians and Gynaecologists (RCOG): Green-top guideline for the management of women with red cell antibodies during pregnancy (2014)

●British Committee for Standards in Haematology (BCSH): Guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn (2013)

Australia–New Zealand

●Australian Red Cross Blood Service and the National Blood Authority (NBA): Expert panel consensus position statement regarding the use of Rh(D) immunoglobulin in patients with a body mass index >30

●New Zealand College of Midwives: Consensus statement – Anti-D prophylaxis administration during pregnancy and early postpartum (2021)

●Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) and NBA: Guideline for the prophylactic use of Rh D immunoglobulin in pregnancy care (2021)

●Australian Red Cross Lifeblood: Haemolytic disease of the fetus and newborn (updated 2020)

●New Zealand Blood Services (NZBS): Use of Rh D immunoglobulin (anti-D immunoglobulin) during pregnancy and the post partum period (2020)

●RANZCOG: Guidelines for the use of Rh(D) immunoglobulin (anti-D) in obstetrics (2019)

●HYPERLINK "https://www1.health.nsw.gov.au/pds/Pages/doc.aspx?dn=GL2015_011" \o "https://www1.health.nsw.gov.au/pds/Pages/doc.aspx?dn=GL2015_011"New South Wales Ministry of Health (NSW Health): Guideline on maternity – Rh (D) immunoglobulin (anti D) (2015)